What is Lifesci Capital’s Estimate for VERV FY2024 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV) – Investment analysts at Lifesci Capital boosted their FY2024 EPS estimates for shares of Verve Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Lifesci Capital analyst C. Jubinville now anticipates that the company will post earnings of ($2.49) per share for the year, up from their prior forecast of ($2.62). The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.65) per share.

VERV has been the subject of several other reports. Canaccord Genuity Group increased their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, HC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verve Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.75.

Verve Therapeutics Price Performance

Shares of NASDAQ:VERV opened at $6.31 on Friday. The business’s 50-day moving average is $5.48 and its 200 day moving average is $5.70. Verve Therapeutics has a 1 year low of $4.30 and a 1 year high of $19.34. The firm has a market capitalization of $534.20 million, a P/E ratio of -2.59 and a beta of 1.75.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The business had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business’s quarterly revenue was up 120.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.72) earnings per share.

Institutional Trading of Verve Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its holdings in shares of Verve Therapeutics by 908.4% during the second quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after purchasing an additional 6,949 shares during the last quarter. Creative Planning purchased a new position in shares of Verve Therapeutics during the 3rd quarter valued at about $50,000. PFG Investments LLC acquired a new position in shares of Verve Therapeutics in the 3rd quarter valued at about $53,000. Daiwa Securities Group Inc. boosted its stake in shares of Verve Therapeutics by 89.8% in the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after buying an additional 5,723 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. grew its holdings in Verve Therapeutics by 13.5% during the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after acquiring an additional 1,778 shares during the period. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.